Zwelling L A, Chan D, Hinds M, Mayes J, Silberman L E, Blick M
Department of Medical Oncology, University of Texas, M.D. Anderson Hospital and Tumor Institute, Houston 77030.
Cancer Res. 1988 Dec 1;48(23):6625-33.
Tumor-promoting phorbol esters such as phorbol 12-myristate 13-acetate (PMA) induce the monocytoid differentiation of HL-60 human leukemia cells. The cellular receptor for PMA is protein kinase C. However, cellular events distal to protein kinase C phosphorylation are also critical steps toward differentiation. These events may include specific programs of oncogene transcription that have been associated with phorbol ester-induced leukemic cell differentiation. Recently, it has been found that topoisomerase II could be activated by protein kinase C-mediated serine phosphorylation and that PMA treatment of HL-60 cells enhanced extractable topoisomerase II from these cells. Additionally, topoisomerase II-reactive antineoplastic drugs could block PMA-induced differentiation of HL-60. This enzyme has been implicated in gene regulation, and drug-induced, topoisomerase II-mediated DNA cleavage sites have been identified within cellular oncogenes. Thus, topoisomerase II could play a critical role in the signal transduction cascade leading from PMA-protein kinase interaction to monocytoid differentiation. We have examined this relationship between topoisomerase II and PMA-induced differentiation through measurements of drug-induced, topoisomerase II-mediated DNA cleavage (via alkaline elution) in PMA-treated HL-60 cells. Etoposide-induced DNA cleavage was reduced 10-fold in HL-60 cells treated with 10 nM PMA for 24 h. Neither dimethyl sulfoxide (which produces granulocytoid differentiation) nor non-differentiation-inducing phorbol esters could produce this effect. The decreased cleavage was not due to a PMA-induced inhibition of cell-associated etoposide and was demonstrable in nuclei isolated from PMA-treated cells. The decrease was not simply related to decreased cellular proliferation rate as reflected in the inhibition of DNA synthesis because conditions leading to marked inhibition of DNA synthesis did not necessarily inhibit etoposide-induced DNA cleavage. By contrast, lower concentrations of PMA inhibited etoposide-mediated DNA cleavage disproportionately compared with PMA effects on DNA synthesis. Interestingly, PMA reduced cleavage induced by the topoisomerase II-reactive DNA intercalator 4'-(9-acridinylamino)methanesulfon-m-anisidide by 2-fold, suggesting that specific drug-DNA interactions could partially overcome the PMA-induced effect that resulted in decreased etoposide-induced, topoisomerase II-mediated DNA cleavage. Nuclear proteins in 0.35 M NaCl extracts from untreated or PMA-treated HL-60 cells were virtually identical in topoisomerase II activity and in topoisomerase II-associated drug sensitivity.(ABSTRACT TRUNCATED AT 400 WORDS)
肿瘤促进性佛波酯,如佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA),可诱导HL - 60人白血病细胞向单核细胞样分化。PMA的细胞受体是蛋白激酶C。然而,蛋白激酶C磷酸化之后的细胞事件也是分化过程中的关键步骤。这些事件可能包括与佛波酯诱导的白血病细胞分化相关的癌基因转录特定程序。最近发现,拓扑异构酶II可被蛋白激酶C介导的丝氨酸磷酸化激活,并且用PMA处理HL - 60细胞可增强这些细胞中可提取的拓扑异构酶II。此外,拓扑异构酶II反应性抗肿瘤药物可阻断PMA诱导的HL - 60细胞分化。该酶与基因调控有关,并且在细胞癌基因内已鉴定出药物诱导的、拓扑异构酶II介导的DNA切割位点。因此,拓扑异构酶II可能在从PMA - 蛋白激酶相互作用到单核细胞样分化的信号转导级联反应中起关键作用。我们通过测量药物诱导的、拓扑异构酶II介导的DNA切割(通过碱性洗脱),在经PMA处理的HL - 60细胞中研究了拓扑异构酶II与PMA诱导的分化之间的这种关系。在用10 nM PMA处理24小时的HL - 60细胞中,依托泊苷诱导的DNA切割减少了10倍。二甲基亚砜(可诱导粒细胞样分化)和非分化诱导性佛波酯均不能产生这种效果。切割减少并非由于PMA诱导的细胞相关依托泊苷抑制,并且在从PMA处理的细胞中分离的细胞核中也可证实。这种减少并非简单地与细胞增殖速率降低相关,因为DNA合成受到抑制所反映的情况并不一定抑制依托泊苷诱导的DNA切割。相比之下,较低浓度的PMA与PMA对DNA合成的影响相比,对依托泊苷介导的DNA切割的抑制作用不成比例。有趣的是,PMA使拓扑异构酶II反应性DNA嵌入剂4' -(9 - 吖啶基氨基)甲磺酰基 - 间 - 茴香胺诱导的切割减少了2倍,这表明特定的药物 - DNA相互作用可部分克服PMA诱导的导致依托泊苷诱导的、拓扑异构酶II介导的DNA切割减少的效应。未经处理或经PMA处理的HL - 60细胞的0.35 M NaCl提取物中的核蛋白在拓扑异构酶II活性和与拓扑异构酶II相关的药物敏感性方面几乎相同。(摘要截短至400字)